E I Gusev Selected Research

E I Gusev Research Topics

Disease

32	Multiple Sclerosis 01/2017 - 01/2000
19	Ischemic Stroke 01/2022 - 01/2000
16	Stroke (Strokes) 01/2015 - 01/2000
6	Epilepsy (Aura) 01/2008 - 01/2001
5	Relapsing-Remitting Multiple Sclerosis 01/2022 - 01/2002
5	Parkinson Disease (Parkinson's Disease) 01/2020 - 01/2002
3	Nervous System Diseases (Neurological Disorders) 01/2015 - 06/2004
3	Atrophy 01/2013 - 01/2000
2	Seizures (Absence Seizure) 01/2021 - 01/2001
2	Prodromal Symptoms 01/2021 - 01/2020
2	Optic Neuritis (Retrobulbar Neuritis) 01/2018 - 11/2002
2	Inflammation (Inflammations) 01/2015 - 01/2004
2	Cerebrovascular Disorders (Cerebrovascular Occlusion) 01/2015 - 01/2005
2	Demyelinating Diseases (Demyelinating Disease) 01/2015 - 01/2002
2	Neoplasms (Cancer) 01/2015 - 01/2015
2	Necrosis 01/2015 - 10/2002
2	Genetic Predisposition to Disease (Genetic Predisposition) 09/2009 - 08/2003
2	Brain Diseases (Brain Disorder) 03/2007 - 01/2003
2	Hemorrhagic Stroke 01/2007 - 01/2005
2	Movement Disorders (Movement Disorder) 01/2006 - 01/2004
2	Tremor (Tremors) 01/2004 - 01/2002
2	Sclerosis 01/2003 - 01/2002
2	Hypertension (High Blood Pressure) 01/2003 - 01/2002
1	Body Weight (Weight, Body) 01/2022
1	Bradycardia 01/2021
1	Heart Arrest (Cardiac Arrest) 01/2021
1	Consciousness Disorders 01/2021
1	Synucleinopathies 01/2020
1	Cerebral Hemorrhage 01/2019
1	Myocardial Infarction 01/2018
1	Tricuspid Valve Prolapse 01/2015
1	Myocardial Ischemia (Ischemic Heart Diseases) 01/2015
1	Autoimmune Diseases of the Nervous System 01/2015
1	Amyloid Plaque 01/2015
1	Chronic Progressive Multiple Sclerosis 01/2013
1	Ganglion Cysts (Ganglion) 01/2012

Drug/Important Bio-Agent (IBA)

7	InterferonsIBA 01/2022 - 01/2000
6	Interferon beta-1a FDA Link 01/2022 - 01/2003
6	Neuroprotective AgentsIBA 01/2013 - 01/2000
6	Glatiramer Acetate (Copaxone)FDA Link 01/2012 - 01/2002
5	AutoantibodiesIBA 01/2008 - 01/2000
4	Levodopa (L Dopa)FDA LinkGeneric 01/2020 - 01/2004
4	Interferon-betaIBA 01/2011 - 01/2000
4	AntigensIBA 06/2004 - 01/2002
3	Anticonvulsants (Antiepileptic Drugs)IBA 01/2021 - 01/2008
3	Biomarkers (Surrogate Marker)IBA 01/2020 - 01/2002
3	AntibodiesIBA 01/2015 - 04/2001
3	Fibrinogen (Factor I)FDA Link 01/2012 - 01/2008
3	Interferon beta-1b (Betaseron)FDA Link 01/2006 - 01/2000
3	Glutamic Acid (Glutamate)FDA Link 10/2002 - 01/2000
3	Aspartic Acid (Aspartate)FDA Link 10/2002 - 01/2000
3	Glycine (Aminoacetic Acid)FDA LinkGeneric 01/2001 - 01/2000
3	gamma-Aminobutyric Acid (GABA)IBA 01/2001 - 01/2000
2	Tissue Plasminogen Activator (Alteplase)FDA Link 01/2022 - 01/2018
2	Pro-Gly-Pro- ACTH (4-7)IBA 01/2018 - 01/2005
2	cerebrolysinIBA 01/2013 - 01/2007
2	Interleukin-6 (Interleukin 6)IBA 01/2012 - 01/2002
2	Acetates (Acetic Acid Esters)FDA Link 01/2012 - 01/2011
2	CTLA-4 AntigenIBA 11/2011 - 07/2002
2	Betahistine (Serc)IBA 01/2011 - 01/2002
2	SteroidsIBA 01/2006 - 01/2003
2	histochromeIBA 11/2005 - 01/2005
2	Myelin Basic ProteinIBA 11/2003 - 08/2003
2	Heroin (Diamorphine)IBA 01/2003 - 01/2001
2	DNA (Deoxyribonucleic Acid)IBA 01/2003 - 04/2001
2	Mesylates (Mesylate)IBA 01/2003 - 01/2002
2	eprosartan (Teveten)FDA Link 01/2003 - 01/2002
2	HLA-DRB1 Chains (HLA DRB1)IBA 11/2002 - 01/2000
2	Neurotransmitter Agents (Neurotransmitter)IBA 10/2002 - 01/2001
2	Carrier Proteins (Binding Protein)IBA 10/2002 - 01/2000
1	Staphylococcus aureus auR protein (staphylokinase)IBA 01/2022
1	Potassium Channel Blockers (Blockers, Potassium Channel)IBA 01/2021
1	SphingolipidsIBA 01/2021
1	SphingomyelinsIBA 01/2020
1	von Willebrand FactorIBA 01/2019
1	Fibrinolysin FDA Link 01/2018
1	Streptokinase FDA Link 01/2018
1	Brain-Derived Neurotrophic Factor (BDNF)IBA 01/2018
1	Cytokine Receptors (Cytokine Receptor)IBA 01/2016
1	Contrast MediaIBA 01/2015
1	GadoliniumIBA 01/2015
1	HDL LipoproteinsIBA 01/2015
1	Cytostatic AgentsIBA 01/2015
1	Alemtuzumab (Campath)FDA Link 01/2013
1	Monoclonal AntibodiesIBA 01/2013
1	laquinimodIBA 01/2013
1	Biosimilar PharmaceuticalsIBA 01/2013
1	Cytidine Diphosphate Choline (Citicoline)IBA 01/2012
1	antineoplaston A10 (A 10)IBA 01/2012
1	Protons (Proton)IBA 01/2012
1	Retinaldehyde (Retinal)IBA 01/2012
1	CCR5 Receptors (CCR5 Receptor)IBA 11/2011
1	Histocompatibility Antigens Class IIIBA 11/2011
1	Interleukin-7 Receptor alpha SubunitIBA 11/2011

Therapy/Procedure

21	Therapeutics 01/2022 - 01/2000
2	Thrombolytic Therapy 01/2022 - 01/2018
2	Aftercare (After-Treatment) 01/2013 - 01/2005
1	Intramuscular Injections 01/2022
1	Plasmapheresis 01/2015
1	Immunotherapy 11/2011